Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.63 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.60 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 3/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.50 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12131750 | 0.90 | ERCC1 (0.70) | MEN1KMT2AERCC1ERCC4CYP2C19 | |
| SCHEMBL11294240 | 0.87 | MEN1 (0.61) | MEN1KMT2ARAB9ASMN1; SMN2CYP2C19 | |
| SCHEMBL20438751 | 0.86 | CARM1 (0.66) | MEN1KMT2ARAB9ASMN1; SMN2CYP2C19 | |
| SCHEMBL11733691 | 0.86 | MEN1 (0.59) | MEN1KMT2ARAB9ASMN1; SMN2CYP2C19 | |
| SCHEMBL13169668 | 0.85 | ERCC1 (0.60) | MEN1KMT2AERCC1ERCC4RAB9A | |
| SCHEMBL24558042 | 0.85 | ERCC1 (0.64) | MEN1KMT2AERCC1ERCC4CYP2C19 | |
| Bromide SCHEMBL11102143 | 0.84 | CARM1 (0.64) | MEN1KMT2ARAB9ASMN1; SMN2CYP2C19 | |
| SCHEMBL5023255 | 0.84 | TSHR (0.60) | MEN1KMT2ARAB9ASMN1; SMN2CYP2C19 | |
| SCHEMBL15038484 | 0.83 | ALDH1A1 (0.50) | MEN1KMT2AERCC1ERCC4RAB9A | |
| SCHEMBL12134066 | 0.83 | ERCC1 (0.62) | MEN1KMT2AERCC1ERCC4RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190327969-A1 | HERBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2019-10-31 | — | — | US | disclosed |
| US-10017522-B2 | Alpha helix mimetics and methods relating thereto | Prism BioLab Co., Ltd. (JP) | 2018-07-10 | — | — | US | disclosed |
| US-9656962-B2 | Ring-contracted morphinans and the use thereof | PURDUE PHARMA L.P. (US) | 2017-05-23 | — | — | US | disclosed |
| EP-1688418-B1 | Chemokine receptor antagonists and methods of use thereof | MILLENNIUM PHARM INC (US) | 2017-03-15 | — | — | EP | disclosed |
| US-8629157-B2 | Pyrrolidine compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
| US-20110312974-A1 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-12-22 | — | — | US | disclosed |
| US-8058287-B2 | Chemokine receptor antagonists and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| US-20110190227-A1 | Antagonists of Prostaglandin D2 Receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190227-A1 | Antagonists of Prostaglandin D2 Receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-7910609-B2 | Inhibitors of integrin alpha2beta1 with modified urea moiety | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2011-03-22 | — | — | US | disclosed |
| US-7910609-B2 | Inhibitors of integrin alpha2beta1 with modified urea moiety | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2011-03-22 | — | — | US | disclosed |
| US-20090281081-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090197861-A1 | INHIBITORS OF INTEGRIN ALPHA2BETA1 WITH MODIFIED UREA MOIETY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-08-06 | — | — | US | disclosed |
| US-20090197861-A1 | INHIBITORS OF INTEGRIN ALPHA2BETA1 WITH MODIFIED UREA MOIETY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-08-06 | — | — | US | disclosed |
| WO-2004089297-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF THROMBOSIS | SUNTORY PHARMACEUTICAL RESEARCH LABORATORIES, LLC (US) | 2004-10-21 | — | — | WO | disclosed |
| EP-0356026-A2 | Azo amide compounds | WAKO PURE CHEMICAL INDUSTRIES LTD (JP) | 1990-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312974-A1 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGER2 | MEN1 4828/4885KMT2A 4142/4885ERCC1 4541/4885 |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | MEN1 4874/4885KMT2A 3551/4885ERCC1 3805/4885 |
| US-20090281081-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | ACKR3, CCL11, CCR7 | MEN1 4167/4885KMT2A 4480/4885ERCC1 4490/4885 |
| US-20190327969-A1 | HERBICIDES | DDT, HPD, PDXK | MEN1 4350/4885KMT2A 884/4885ERCC1 3780/4885 |
| US-20110190227-A1 | Antagonists of Prostaglandin D2 Receptors | PTGDR, PTGDR2, PTGER2 | MEN1 4760/4885KMT2A 4618/4885ERCC1 4245/4885 |
| US-10017522-B2 | Alpha helix mimetics and methods relating thereto | PLOD3, COL1A1, THPO | MEN1 1064/4885KMT2A 3392/4885ERCC1 3598/4885 |
| US-20090197861-A1 | INHIBITORS OF INTEGRIN ALPHA2BETA1 WITH MODIFIED UREA MOIETY | ITGA2B, ITGA2, ITGB2 | MEN1 4541/4885KMT2A 3126/4885ERCC1 1996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.